spironolactone has been researched along with atenolol in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barclay, SC; Gibson, J; Lamey, PJ; Miller, S | 1 |
| Cocco, F; Dessì Fulgheri, P; Dettori, S; Fiori, C; Glorioso, N; Madeddu, P; Rappelli, A; Sanna, G | 1 |
| Diamond, JA | 1 |
| Burnier, M; Pechère, A; Waeber, B | 1 |
| Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA | 1 |
| Amiri, F; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Dabrowski, R; Michalak, E; Sosnowski, C; Szwed, H | 1 |
| Bhadada, SV; Patel, BM | 1 |
| Baez, A; Bazán, C; Camino Willhuber, GO; Fretes, R; Guzman Mentesana, G; Lo Presti, S; Paglini-Oliva, PA; Rivarola, HW; Strauss, M | 1 |
1 review(s) available for spironolactone and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for spironolactone and atenolol
| Article | Year |
|---|---|
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response Relationship, Drug; Female; Fibrosis; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Peptide Fragments; Procollagen; Propanolamines; Prospective Studies; Radioimmunoassay; Spironolactone | 2007 |
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Blood Pressure; Buttocks; Collagen; Diastole; Double-Blind Method; Elasticity; Elastin; Eplerenone; Female; Humans; Hypertension; Inflammation Mediators; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myography; Spironolactone; Subcutaneous Tissue; Systole; Vascular Resistance | 2008 |
16 other study(ies) available for spironolactone and atenolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Grinspan's syndrome: a drug-induced phenomenon?
Topics: Aged; Aged, 80 and over; Atenolol; Bendroflumethiazide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Female; Furosemide; Glipizide; Humans; Hypertension; Lichen Planus; Metformin; Middle Aged; Mouth Diseases; Spironolactone; Syndrome | 1990 |
[Role of renin profile and age in the choice of the therapeutic approach of arterial hypertension (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atenolol; Chlorthalidone; Diuretics; Drug Therapy, Combination; Humans; Hypertension; Metoprolol; Middle Aged; Prazosin; Renin; Sotalol; Spironolactone | 1981 |
Recent onset severe hypertension requiring multiple antihypertensive medications.
Topics: Aged; Antihypertensive Agents; Atenolol; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Severity of Illness Index; Spironolactone; Treatment Outcome | 2001 |
[Antihypertensive agents used as first line agents: beta-blockers under pressure].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Dihydropyridines; Diuretics; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Spironolactone; Treatment Outcome | 2006 |
A beneficial effect of 3-year spironolactone therapy supplementing atenolol therapy on the remodeling of atria and ventricles in a patient with permanent atrial fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Heart Atria; Heart Ventricles; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2009 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Metoprolol; Perindopril; Ramipril; Rats, Wistar; Spironolactone | 2014 |
[Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications]
Topics: Animals; Antihypertensive Agents; Atenolol; Cardiotonic Agents; Digoxin; Disease Models, Animal; Diuretics; Electrocardiography; Enalapril; Female; Furosemide; Heart Failure; Isosorbide Dinitrate; Male; Mice; Mitochondria, Heart; Spironolactone | 2017 |